Cite
HARVARD Citation
Wetzel, C. et al. (2021). Loss of HER2‐positivity following neoadjuvant targeted therapy for breast cancer is not associated with inferior oncologic outcomes. Journal of surgical oncology. 124 (8), pp. 1224-1234. [Online].